Navigation Links
KaloBios Announces Fiscal Year 2012 Financial Results
Date:3/27/2013

nts and marketable securities totaling $20.3 million, compared to $17.8 million at December 31, 2011. On a pro-forma basis at December 31, 2012, including the net proceeds of our initial public offering completed in the first quarter of 2013, the cash, cash equivalent and marketable securities was approximately $83.8M. 

"KaloBios ended 2012 with a strong, differentiated clinical pipeline marked by three first-in-class, patient-targeted therapies for severe asthma, Pseudomonas infections associated with cystic fibrosis and pneumonia, and hematologic malignancies," said David Pritchard, KaloBios' President and Chief Executive Officer. "We continue to move forward aggressively to complete enrollment in the ongoing Phase 2 KB003 asthma study, our Phase 2 KB001-A cystic fibrosis (CF) study and our Phase 1 KB004 hematologic malignancy study."

Anticipated Upcoming Milestones for 2013-20142Q 2013:

File for Orphan Drug Status in the USA and European Union for KB001-A in CF3Q 2013:

Full recruitment of the KB003 asthma study3Q 2013:

Initiation of the expansion phase of the KB004 study in AML with EphA3 diagnostic test4Q 2013:

Full recruitment of the KB001-A CF study 1Q 2014:

Initiation of Phase 2 KB004 study in at least one new indication 1Q 2014:

Top line KB003 Phase 2 asthma study results2Q 2014:

Top line KB001-A CF study results3Q/4Q 2014:

Initiation of Sanofi Phase 2b study for prevention of ventilator-associated pneumonia (VAP) 4Q 2014:

Completion of enrollment in at least one hematologic malignancy indication in the expansion phase of KB004 About KaloBiosKaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Currently, KaloBios has three drug development programs:

  • KB0
    '/>"/>

  • SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. CfPIE Announces Advisory Board to Support Continued Life Sciences Training Alignment with Industry Regulations
    2. SoundConnect Announces Audio Conferencing Capacity Upgrades
    3. BMI Surplus Announces Sale of Thermal Vacuum Space Simulation Chamber
    4. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
    5. National Brain Tumor Society Announces Launch of Defeat GBM Research Collaborative
    6. Regenerative Medicine Company, Eqalix, Announces Grant from Nanotechnology Institute in Philadelphia, Pennsylvania
    7. Probiotics Are in More Than Just Yogurt: Probiotic Action Announces 5 New Items Containing the Healthy Bacteria
    8. Synedgen Announces Issuance of Patent to Optimize Animal Health
    9. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
    10. Probiotic Action Announces Probiotics Pending Listing on EU Foods
    11. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
    (Date:7/28/2015)... , ... July 28, 2015 , ... VetStem Biopharma will ... stem cell credentialing course to local area veterinarians. , The tour and course will ... units at no charge) at VetStem’s Poway facility. Staff members are welcome to attend ...
    (Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
    (Date:7/28/2015)... RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United ... its financial results for the second quarter ended ... nearly 300% as compared to the second quarter ... said Roger Jeffs, Ph.D., United Therapeutics, President and ... was due to an increase in the number ...
    Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
    ... magnetic head to ride consistently on a cushion of air ... enough. But, try to do it profitably when the technology ... , ,This is the dilemma for Hutchinson Technology ... three quarters of the world's computer disk drives. But it's ...
    ... Fitchburg, Wis. - Judy Faulkner, founder and CEO of ... Madisons monthly meeting held at the Promega BTC Center. The ... operations of this unique, and successful company. , ,For over ... at association events. She does not participate on outside company ...
    ... Recently, I was at a security conference and stayed at ... day. They claimed that they had implemented it so only ... , ,I do not purchase wireless Internet service when ... network at the seminar hosts office. Out of curiosity, on ...
    Cached Biology Technology:Eau Claire Manufacturer Drives Your PC 2Eau Claire Manufacturer Drives Your PC 3Epic's Founder Judy Faulkner Speaks on Culture, Business Beliefs, and Recruiting: WTN Exclusive Coverage 2Epic's Founder Judy Faulkner Speaks on Culture, Business Beliefs, and Recruiting: WTN Exclusive Coverage 3Wireless Are you at Risk and Liable? 2Wireless Are you at Risk and Liable? 3Wireless Are you at Risk and Liable? 4
    (Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
    (Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
    (Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
    Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
    ... of Hepatitis C (PEDS-C) trial reveals that children treated ... significant changes in height, weight, body mass index (BMI), ... of Hepatology , a journal of the American ... most growth-related side effects are reversible with cessation of ...
    ... grapes may help protect heart health in people with ... Journal of Nutrition . Researchers observed ... in men with metabolic syndrome: reduced blood pressure, improved ... in grapes, known as polyphenols, are thought to be ...
    ... MD August 9, 2012 -- As upper level ... semester, the Genetics Society of America,s GENETICS journal offers ... are designed to bring cutting-edge scientific research into the ... The principal learning goal of the ...
    Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2Eating grapes may help protect heart health in men with metabolic syndrome, new study suggests 2New Genetics educational resource promotes active learning 2
    Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
    ...
    ... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
    ... A-20 cells were cultured in RPMI 1640 with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
    Biology Products: